Tirzepatide, a first-in-class GIP/GLP-1 receptor agonist, resulted in significant improvements in HbA1c and body weight compared to insulin lispro (iLispro) at 52 weeks in the SURPASS-6 study. We compared the HRQoL of participants with T2D treated with tirzepatide (all doses pooled) versus iLispro, both added to basal insulin, in SURPASS-6.
Adults with T2D and inadequate glycemic control were randomized (1:1:1:3) to tirzepatide 5, 10, or 15 mg QW, or iLispro TID, as add-on to optimized insulin glargine, with or without metformin, for 52 weeks in this open-label, multicenter, Phase 3b study. HRQoL was measured at baseline and endpoint (Week 52) using the SF-36v2 acute form comprised of 8 domains and 2 component summary scores.
Overall, 1428 participants with mean baseline age 59 y, T2D duration 14 y, HbA1c 8.8% and BMI 33.1 kg/m2 were randomized. At endpoint, tirzepatide-treated participants had statistically significantly improved scores across all SF-36v2 domains and component summaries compared to iLispro-treated participants, with the largest differences observed in the General health (LS mean [SE] change 3.0 [0.31] vs. -0.1 [0.32]) and Vitality (1.5 [0.31] vs. -1.1 [0.32]) domains (Table).
Tirzepatide treatment resulted in greater improvements across multiple domains of HRQoL than iLispro in adults with long standing T2D already treated with basal insulin.
K.Boye: Employee; Eli Lilly and Company. H.Sapin: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. J.Poon: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. L.Fernandez lando: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. R.Huh: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. M.Wang: None. H.Patel: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.
Eli Lilly and Company
